Search research articles
Contact Us
Filters
Showing results (111-120 of 130) with videos related to
Page
of 13
Sort By:
European Urology
|
January 22, 2020
Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder
Andrea Necchi, Russell Madison, Daniele Raggi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2026
The pan-tumor landscape of gene amplifications and copy number amplification ratio for established and emerging clinical targets
Jessica K Lee, Julia C F Quintanilha, Kuei-Ting Chen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 4, 2025
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC
Seshiru Nakazawa, Federica Pecci, Biagio Ricciuti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 3, 2016
Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing
Alexa B Schrock, Garrett M Frampton, Dana Herndon, et al.
JCO Precision Oncology
|
December 24, 2021
Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti-PD-1 Therapy
Léa Dousset, Florence Poizeau, Caroline Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2018
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
Jessica J Lin, Viola W Zhu, Satoshi Yoda, et al.
Translational Oncology
|
August 1, 2021
Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors
Jonathan W Riess, Shaila Rahman, Waleed Kian, et al.
The Oncologist
|
September 16, 2017
Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures
Adrienne Johnson, Eric Severson, Laurie Gay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2022
Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience
Steven B Maron, Stephanie Moya, Federica Morano, et al.
Journal of the National Cancer Institute
|
January 26, 2018
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
Filippo Pietrantonio, Federica Di Nicolantonio, Alexa B Schrock, et al.
Page
of 13
Search research articles
Search
Showing results (111-120 of 130) with videos related to
Sort By:
Page
of 13
European Urology
|
January 22, 2020
Comprehensive Assessment of Immuno-oncology Biomarkers in Adenocarcinoma, Urothelial Carcinoma, and Squamous-cell Carcinoma of the Bladder
Andrea Necchi, Russell Madison, Daniele Raggi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 23, 2026
The pan-tumor landscape of gene amplifications and copy number amplification ratio for established and emerging clinical targets
Jessica K Lee, Julia C F Quintanilha, Kuei-Ting Chen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
April 4, 2025
Activating Mutations in the MET Kinase Domain Co-Occur With Other Driver Oncogenes and Mediate Resistance to Targeted Therapy in NSCLC
Seshiru Nakazawa, Federica Pecci, Biagio Ricciuti, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 3, 2016
Comprehensive Genomic Profiling Identifies Frequent Drug-Sensitive EGFR Exon 19 Deletions in NSCLC not Identified by Prior Molecular Testing
Alexa B Schrock, Garrett M Frampton, Dana Herndon, et al.
JCO Precision Oncology
|
December 24, 2021
Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti-PD-1 Therapy
Léa Dousset, Florence Poizeau, Caroline Robert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 27, 2018
Impact of EML4-ALK Variant on Resistance Mechanisms and Clinical Outcomes in ALK-Positive Lung Cancer
Jessica J Lin, Viola W Zhu, Satoshi Yoda, et al.
Translational Oncology
|
August 1, 2021
Genomic profiling of solid tumors harboring BRD4-NUT and response to immune checkpoint inhibitors
Jonathan W Riess, Shaila Rahman, Waleed Kian, et al.
The Oncologist
|
September 16, 2017
Comprehensive Genomic Profiling of 282 Pediatric Low- and High-Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures
Adrienne Johnson, Eric Severson, Laurie Gay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 29, 2022
Epidermal Growth Factor Receptor Inhibition in Epidermal Growth Factor Receptor-Amplified Gastroesophageal Cancer: Retrospective Global Experience
Steven B Maron, Stephanie Moya, Federica Morano, et al.
Journal of the National Cancer Institute
|
January 26, 2018
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer
Filippo Pietrantonio, Federica Di Nicolantonio, Alexa B Schrock, et al.
Page
of 13